UNIVERSITATEA BABES BOLYAI [ UBB ]

MIHAIL KOGALNICEANU 1 400084 CLUJ-NAPOCA - Romania

Involved in the following projects during the 3rd programme

3rd Health Programme (2014-2020)
Managing Frailty. A comprehensive approach to promote a disability-free advanced age in Europe: the ADVANTAGE initiative [ADVANTAGE]
Managing Frailty. A comprehensive approach to promote a disability-free advanced age: the ADVANTAGE initiative
ADVANTAGE will build a common understanding on frailty to be used by Member States on...
Managing Frailty. A comprehensive approach to promote a disability-free advanced age: the ADVANTAGE initiative
ADVANTAGE will build a common understanding on frailty to be used by Member States on which to base a common management approach of older people who are frail or at risk for developing frailty in the European Union.
The identification of the core components of frailty and its management should promote the needed changes in the organization and the implementation of the Health and Social Systems to provide those models of care that, stemming from the particular health profile of each Member State (MS), will allow them to face the challenge of frailty within a common framework.
ADVANTAGE will summarise the current State of the Art for the different components of frailty and its management, both at individual and population level, will collect information on the development of programs to manage frailty in older adults in the EU and will propose, as its main outcome, a common European model to approach frailty. This model will include a road map that, considering the degree of frailty policies� development, will propose interventions for frail and at risk people and will establish tailored milestones for each MS in order to achieve a comprehensive approach to promote a disability-free advanced age. Furthermore, the model will identify gaps of knowledge in the field that would benefit from further research.
Start date: 01/01/2017 - End date: 31/12/2019
Keywords : [ Ageing ] [ Frailty ] [ Function ]

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Prevention of frailty
3rd Health Programme (2014-2020)
prOmoting evidence-bASed rEformS [OASES]
The expression of medical desert is commonly used in the public and mediatic field referring to several situations or areas where people have difficulties to access care (e.g. waiting time, doctor’s...
The expression of medical desert is commonly used in the public and mediatic field referring to several situations or areas where people have difficulties to access care (e.g. waiting time, doctor’s registration difficulties or long distances to hospital).The identification of such areas became a major issue and is exacerbated by the fact that the accessibility itself is complex to address due to its multidimensional nature (spatial, physical, temporal, financial, and cultural).The OASES proposal aims to represent a source of knowledge in European medical deserts, reinforcing the capacity of health authorities of EU Member States to reform their health systems and address all the important aspects to successfully tackle the challenges that the medical desert is posing, with specific regard to actions focusing on skill mix, task shifting, use of e-health and IT systems, recruitment and retention management and policies, in order to guarantee universal coverage also in rural and underserved areas. To achieve this, the proposal presents and supports the application of a stepwise methodology focused on a) definition of a measurement methodology and tool applicable in different contexts (minimal, intermediate, advanced dataset); b) implementation of the measurement methods and tools in selected pilot sites of 7 European countries; c) assessment, policy actions analysis and sustainability in each pilot site, d) impact evaluation in each pilot site and updating the measurement methods and tools according to the pilot results; e) scaling up of the methods and of the policy actions at EU level.
Start date: 01/03/2021 - End date: 29/02/2024

Call: Call for Proposals for Project Grants under the Annual Work Programme 2020 of the 3rd EU Health Programme
Topic: Support to reforms in health workforce field - Initiatives on medical deserts (Heading 1.2.1.1 of the AWP 2020)
3rd Health Programme (2014-2020)
Joint Action to support the eHealth Network [JAseHN]
The overall ambition from EU Member States (MS) is to better include eHealth into health policy and better align eHealth investments to health needs. A central aspect is the transferability of health ...
The overall ambition from EU Member States (MS) is to better include eHealth into health policy and better align eHealth investments to health needs. A central aspect is the transferability of health data across borders of MS and therefore the organizational, technical, semantic and legal interoperability. In order to ensure progress and to bridge the gaps between the governance, strategy and operational levels, a dedicated mechanism for eHealth at EU level has been established: The eHealth Network was formally established in 2011 through the Commission’s Implementing Decision 2011/890/EU based on Art. 14.3 Directive 2011/24/EU and represents the highest decision-making body at EU political level. At a European level there is a strong need to maintain this mechanism and to ensure further common political leadership and ongoing integration of eHealth into health policy in order to continue developing eHealth services responding to health systems‘ needs and health objectives. This is the framework for the Joint Action to support the eHealth Network which is led by the MS and co-financed by the European Commission through a Joint Action.

Hence, the main objective of the Joint Action is to act as the main preparatory body for the eHealth Network. By doing so, the Joint Action aims to develop political recommendations and instruments for cooperation in the four specific priority areas that are specified in the eHealth Network's multi-annual work plan 2015-2018 and that were adopted by the eHealth Network in May 2014:
(1) Interoperability and standardisation,
(2) monitoring and assessment of implementation,
(3) exchange of knowledge and
(4) global cooperation and positioning.

Thereby, the Joint Action functions also as a platform for operational and strategic cooperation between MS on eHealth including their relationship with eHealth Stakeholder Groups and Standardization Organizations.
Start date: 01/05/2015 - End date: 30/06/2018

Call: Grants for actions co-financed with Member State authorities 2014 (Joint Actions)
Topic: eHealth Joint Action
3rd Health Programme (2014-2020)
European Network for Health Technology Assessment (EUnetHTA) - Joint Action 3 [EUnetHTA JA3]
The general objective for EUnetHTA JA3 is to increase the use, quality and efficiency of joint HTA work at European level to support evidence-based, sustainable and equitable choices in healthcare and...
The general objective for EUnetHTA JA3 is to increase the use, quality and efficiency of joint HTA work at European level to support evidence-based, sustainable and equitable choices in healthcare and health technologies and ensure re-use in regional and national HTA reports and activities, in order notably to avoid duplication of assessments. An overarching objective is to develop a general strategy, principles and proposal for a scientific and technical mechanism of permanent sustainable European Collaboration on HTA in the light of the Directive on CBHC. During the JA3 the collaborative production of structured HTA core information, including rapid HTAs will be structurally implemented and the methodologies and production related information and communication technology infrastructure will be finalised as to stand alone from 2020 onwards. EUnetHTA JA3 will also aim to increase the alignment between HTA reports used for reimbursement decisions and clinical practice guidelines that are used by physicians in daily practice. Additionally, EUnetHTA JA3 will also support more alignment of different processes in the lifecycle of health technologies. For instance, processes on market authorization and HTA of pharmaceuticals could be organised in a more closely aligned fashion which may lead to a timelier and more efficient process promoting earlier patient access to products that have a real added value. EUnetHTA JA3 will also contribute to the discussion on the assessment of the effectiveness and safety of new medical devices as is currently taken place as part of the debate on new European legislation for medical devices. Finally, all these outcomes will contribute to the dissemination of health information and knowledge, thus improving policy-and decision-making in the health systems, which turns into protection of citizens against unsafe or ineffective technologies and improves access to high value health technologies. Ultimately this contributes to imTo be developed
Start date: 01/06/2016 - End date: 31/05/2021

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Health Technology Assessment cooperation
3rd Health Programme (2014-2020)
Joint Action on Nutrition and Physical Activity [JANPA]
In all EU Member states (MS), the high level of overweight and obesity in children and adolescents is of particular concern. In the EU, around 1 in 3 children 6-9 years old were overweight or obese in...
In all EU Member states (MS), the high level of overweight and obesity in children and adolescents is of particular concern. In the EU, around 1 in 3 children 6-9 years old were overweight or obese in 2010, a sharp rise in prevalence despite numerous MS or EU initiatives.Physical inactivity and poor diet from birth (and even in utero) are important determinants of adiposity leading to overweight and obesity. They are also independently associated with various non-communicable disease risk factors leading to the main pathologies European populations are suffering from, including detrimental psychosocial outcomes. Overweight and obesity represent an economic burden with up to 7% of EU health budgets spent each year directly on diseases linked to obesity, with more indirect costs resulting from lost productivity. Nutritional problems and physical inactivity need to be addressed in an integrated way so as to promote healthier environments, to make the healthy option the easiest option and to inform and empower families.Within the general frame of the EU Action plan on childhood obesity 2014-2020, the JA’s general objective is to contribute to halting the rise in overweight and obesity in children and adolescents by 2020. Through the, identification, selection and sharing of best data and practices within the 25 countries involved, the JA will allow for : to advocate based on an estimation and forecast of economic cost of overweight and obesity; to improve the implementation of integrated interventions to promote nutrition and physical activity for pregnant women, families with young children; to improve actions within school settings; and to increase the use of nutritional information on foods by public health authorities, stakeholders and families for nutrition policy purposes. The JA will reinforce the links between national nutrition and physical activity policies initiated by the EU Strategy on nutrition, overweight and obesity-related health issues.
Start date: 01/09/2015 - End date: 30/11/2017

Call: Grants for actions co-financed with Member State authorities 2014 (Joint Actions)
Topic: Nutrition and physical activity Joint Action
3rd Health Programme (2014-2020)
Joint Action on Rare Cancers [JARC]
This Joint Action on Rare Cancers (JARC) will be aimed at:

1. prioritising rare cancers (RCs) in the agenda of the Europe (EU) and Member States;
2. developing innovative and shared solutions for ...
This Joint Action on Rare Cancers (JARC) will be aimed at:

1. prioritising rare cancers (RCs) in the agenda of the Europe (EU) and Member States;
2. developing innovative and shared solutions for European Reference Networks (ERNs) on RCs, in the areas of quality of care, innovation, education and state of the art definition on prevention, diagnosis and treatment.
The objectives of JARC will be achieved by creating a platform for competent national authorities as well as institutions, scientific and professional societies and patient organisations, to produce consensus-based recommendations, with a special view to the new ERNs, seen as a great opportunity for improvement of RC patient outcomes in the EU.
Following the results of the RARECARE project, all the 12 families of RCs will be considered. Consensus-based recommendations about RCs will be provided to improve: 1) epidemiological surveillance of RCs; 2) quality of healthcare, primarily through the new ERNs; 3) the availability of clinical practice guidelines on RCs; 4) innovation, also by optimizing clinical research regulations as well as practices and semantics regarding patient data and tissues; 5) medical and patient education; 6) health policy measures on RCs at the EU and national level; 7) patient empowerment (which will be pursued across all items dealt with by JARC). All EU stakeholders in the field of RCs and rare diseases will be involved.
JARC will carry forward the aims of the Third Health Programme by improving chances of EU RC patients to have access to appropriate healthcare, primarily through optimal shaping of ERNs. Thus, all this should result in reduced healthcare inequalities, increased innovation in health, increased sustainability of health systems, decreased health migration and reduction of gaps in rare cancers survival across EU countries.

Start date: 01/10/2016 - End date: 30/09/2019

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Rare cancer